Long-term cardiovascular events after immune checkpoint inhibitor therapy: a nationwide propensity-matched cohort study

Clicks: 2
ID: 323332
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #119 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Immune checkpoint inhibitors (ICIs) have transformed cancer outcomes and are increasingly used. As survival improves, long-term cardiovascular complications have emerged as an important concern. Beyond immune-mediated myocarditis, accumulating evidence suggests broader cardiovascular effects, yet real-world data remain limited by short follow-up, lack of appropriate cancer controls, and residual confounding from established cardiotoxic therapies, leaving long-term ICI-associated cardiovascular risk incompletely defined. Purpose To define the long-term cardiovascular risk associated with ICI therapy using a nationwide, population-based cohort with robust matching and extended follow-up. Methods We conducted a retrospective nationwide cohort study using the Taiwan National Health Insurance Research Database. Adults initiating ICI therapy between 2019 and 2022, during ICI reimbursement era, were compared with cancer patients between 2016 and 2018 without ICI exposure. Patients with prior anthracyclines or anti-HER2 therapy were excluded. Major adverse cardiovascular events (MACE) were defined as a composite of heart failure hospitalization, myocardial infarction, ischemic stroke, or cardiovascular death. Additional cardiovascular outcomes included individual MACE components, coronary artery disease, arrhythmias, peripheral artery disease, and venous thromboembolism. Propensity score matching balanced demographic, cardiovascular and oncologic variables. Hazard ratios were estimated using Cox proportional hazards models at one- and three-year follow-up. Results After propensity score matching, 3,615 ICI-treated patients were compared with 7,230 cancer controls(Table 1). ICI therapy was associated with a higher risk of MACE, with incidence rates of 12.1 versus 6.0 per 100 person-years at one year, corresponding to an almost two-fold increased risk (hazard ratio [HR] 1.94, 95% confidence interval [CI] 1.66–2.26) that persisted at three years (HR 1.89, 95% CI 1.66–2.15). Elevated risks were observed across heart failure hospitalization, coronary artery disease, ischemic stroke, arrhythmias, peripheral artery disease, and cardiovascular death at both one-year and three-year follow-up(Figure 1). Venous thromboembolism was the strongest signal associated with ICI exposure, with a more than three-fold increased risk at one year (HR 3.45, 95% CI 2.81–4.24), driven by elevated risks of deep vein thrombosis (HR 3.25, 95% CI 2.61–4.06) and pulmonary embolism (HR 5.64, 95% CI 3.35–9.51), and persisting through three years (HR 3.52, 95% CI 2.94–4.21)(Figure 1). Conclusions In this nationwide propensity-matched cohort, increased risks of MACE, cardiovascular death, heart failure hospitalization, coronary artery disease, ischemic stroke, and venous thromboembolism persisted through three years, underscoring that ICI-associated cardiovascular risk is long-term, broad in spectrum, and clinically meaningful. Figure 1
Reference Key
openalex_W7172285431 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Y H Hung, C W Liao, C H Tsai, Y J Wu, H J Lin, C S Hung, J K Lee, Y H Lin
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.003
URL
https://doi.org/10.1093/eurheartjsupp/suag097.003
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.